After graduating from Guy’s and St. Thomas’ Medical School in London, Dr Rakesh Popat, MBBS, MRCP, FRCPath, PhD, trained in hematology at St. Bartholomew’s and the Royal London Hospitals, London, UK. He has also completed a PhD focused on designing novel treatment combinations for use in multiple myeloma.
Dr Popat worked in drug discovery at the prestigious Dana Farber Cancer Institute in Boston, MA, after completing a fellowship there. He currently works as a Consultant Hematologist at the NIHR UCLH Clinical Research Facility in London, UK and as an Associate Professor at the UCL Cancer Institute, London, UK.
Dr Popat is the Vice-chair for the UK Myeloma Research Alliance and the North Thames Clinical Research Network Speciality Lead for Hematology.
Speaking on clinical trials for multiple myeloma treatments
Dr Popat’s interests lie in the clinical development of new treatments for hematological cancers, predominantly multiple myeloma. As a leader of the myeloma clinical trials cancer program for the NIHR UCLH Clinical Research Facility, Dr Popat and his team have been responsible for several first-in-human Phase I hematology trials investigating monoclonal antibody treatments. Dr Popat is also the principal investigator of numerous other clinical trials at the NIHR/Wellcome UCH Clinical Research Facility and the UCH Macmillan Cancer Centre in London, UK.